Indaptus Therapeutics, Inc. (INDP)
Health Care · Biotechnology · NASDAQ
Indaptus Therapeutics is a biotechnology firm pivotally shifting its strategy from a discontinued bacterial-based immunotherapy program toward identifying new strategic investments or business combinations.
What Indaptus Therapeutics, Inc. does
Indaptus Therapeutics is a clinical-stage biotechnology company that historically developed a systemically-administered immunotherapy platform based on non-pathogenic, Gram-negative bacteria designed to activate innate and adaptive immune responses. The company has currently discontinued clinical development of its lead candidate, Decoy20, and is evaluating strategic alternatives, including potential business combinations, investments in other operating businesses, and new research initiatives in neurological and sleep-related functions.
Recent developments
In June 2026, the company completed a $12.0 million private placement of common stock. It has discontinued all clinical enrollment for its Decoy20 program and is actively evaluating strategic alternatives, including potential acquisitions of operating businesses or new research collaborations in neurology and sleep.
From Indaptus Therapeutics, Inc.'s filing of 2026-08-13.
Themes: immunotherapy / oncology, neurological research / sleep disorders, strategic transformation / corporate pivot
Fundamentals
- Price$2.96 as of 2026-10-20 close
- Market cap$394M as of 2026-08-13 (share count; price 2026-10-20)
- 1-year return-24.1% 2025-10-20 close $3.90 → 2026-10-20 close $2.96
- P/En/a negative earnings
- ROE-661.5% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.01 as of 2026-09-02
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How INDP compares in its sector
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$2M | -$2M | -$0.02 | -$2M† |
| Q1 FY2026 2026-03-31 | -$2M | -$3M | -$0.23 | -$7M |
| Q4 FY2025 2025-12-31 | -$8M† | -$8M† | -$3.10† | -$3M† |
| Q3 FY2025 2025-09-30 | -$3M | -$3M | -$2.98 | -$3M† |
| Q2 FY2025 2025-06-30 | -$4M | -$5M | -$9.09 | -$4M† |
| Q1 FY2025 2025-03-31 | -$5M | -$5M | -$9.11 | -$5M |
| Q4 FY2024 2024-12-31 | -$4M† | -$4M† | -$10.43† | -$3M† |
| Q3 FY2024 2024-09-30 | -$3M | -$3M | -$9.04 | -$3M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$8M
- Short-term investments$4M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Indaptus Therapeutics, Inc. looks technically
Indaptus Therapeutics, Inc. (INDP) is trading 30.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 39 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 19 trading days ago. It is 50.3% below its highest point of the past year. Trading volume is unusually light — only about 17% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 30.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +30.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.20 | $2.20 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.28 | $2.28 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 1.94. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 39 trading days ago — a "death cross", a bearish long-term signal | 39 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 30.0% above | +30.0% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30) | 55.5 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($1.94 to $2.97) — its "stochastic" reading is 99 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 99.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.96 | $5.96 |
|---|---|---|
| From the 52-week high | it is 50.3% below its 52-week high (its highest price of the past year) | -50.3% |
| Above the 52-week low | it is 221.7% above its 52-week low (its lowest price of the past year) | +221.7% |
| Below the 52-week high | it is 50.3% below its highest point of the past year | 50.3% |
| Since a 20-day breakout | it made a new 20-day high about 19 trading days ago | 19 sessions |
| Since a 55-day breakout | it made a new 55-day high about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $21952.00 (set on 2017-09-26) | $21952.00 |
| Given back of the 52-week move | over the past year its closes ranged ($0.936 to $4.75), and it has recovered around half of its fall from last year’s high — 53% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.29 to $3.42. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 53.1% |
| From the all-time high | it is 100.0% below its all-time high | -100.0% |
| Nearest price level | it is trading 1.0% above a support level at $2.93 — a price it turned at twice since 2025-12-09, most recently on 2026-07-23. Since 2024-10-21 it has 5 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.0% |
| All-time low | its lowest closing price on record is $0.92 (set on 2026-08-18) | $0.92 |
| Above the all-time low | it is 221.7% above its all-time low | +221.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 75% of it) | 25th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3989 between its high and its low — about 13.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3989 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.66 and $3.84 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.66 – $2.75 – $3.84 |
| Typical daily range (% of price) | its price moves about 13.5% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 13.5% |
| Stretch from the 200-day average | it is trading 1.7 daily ranges above its 200-day average price (30.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 17% of its 30-day average | 0.17× |
|---|
Candlestick patterns
1
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Open gap | it gapped 3.8% above the previous close 29 sessions ago and has not traded back through the level it left behind at 1.85 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.8% |
| Gap filled | a 3.0% gap down opened on 2026-10-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +12.55% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 17.6 percentage points (the stock lost 16.6% while the market gained 1.0%) | -17.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.7 percentage points (the stock gained 20.3% while the market gained 3.6%) | +16.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 26.5 percentage points (the stock lost 18.0% while the market gained 8.5%) | -26.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 38.7 percentage points (the stock lost 24.1% while the market gained 14.6%) | -38.7% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 41% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.0% of the share price, which is taken to mean a barrier that gives way easily. | +41.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.22 — a volume-weighted average of daily closes over 201 sessions, not a true tick-by-tick VWAP. | -8.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% below the average price paid since it last reported on 2026-03-17 (its 10-K), so the typical buyer over that stretch is under water. That average is $3.24 — a volume-weighted average of daily closes over 151 sessions, not a true tick-by-tick VWAP. | -8.8% |
Price levels it has turned at before
INDP last closed at $2.96 on 2026-10-20. Since 2024-10-21 it has turned at 5 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.93 | Support | 1.0% below the last close | turned there twice · 2025-12-09 to 2026-07-23 |
| $2.40 | Support | 18.8% below the last close | turned there twice · 2026-01-07 to 2026-07-08 |
| $1.93 | Support | 34.7% below the last close | turned there twice · 2025-12-23 to 2026-10-02 |
| $8.63 | Resistance | 191.6% above the last close | turned there twice · 2025-08-13 to 2025-09-26 |
| $13.42 | Resistance | 353.4% above the last close | turned there twice · 2025-05-14 to 2025-07-10 |
| $19.77 | Resistance | 567.8% above the last close | turned there twice · 2025-02-25 to 2025-06-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $1.94.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $5.24 and $7.28 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $1.94.
This reading has stood for 8 trading days, since 2026-10-09.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["Significant uncertainty regarding future business direction and viability following the discontinuation of clinical trials.","History of operating losses and dependence on future financing to fund operations and potential strategic acquisitions.","Management transition and operational risks related to identifying and executing a new corporate strategy or business combination."]
What changed in the latest 10-Q
AI-assisted comparison of INDP's 10-Q filed 2026-08-13 against the prior one filed 2026-05-15.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-13) adds: 'During the second quarter of 2026, we also began evaluating our strategic alternatives, including a potential Post-Investment Transaction, involving an investment in or acquisition of an operating business, while continuing to evaluate our existing therapeutic assets and related research initiatives.'
- Newer filing (2026-08-13) adds: 'During the second quarter of 2026, we discontinued further enrollment in our combination study, there are no participants remaining in any active Decoy20 clinical study, and we substantially reduced activities related to the further development of Decoy20 while we evaluate strategic alternatives for our business and therapeutic assets.'
- Newer filing (2026-08-13) adds: 'During the second quarter of 2026, we also started a research collaboration with Kunming University of Science and Technology in the areas of neurological research and sleep, which we are evaluating as a complementary research initiative while we continue to evaluate the Company's Decoy platform and Decoy20 assets from a scientific and strategic perspective, including the existing data, mechanism of action, potential applications, and possible licensing, partnership or other strategic opportunities.'
- Newer filing (2026-08-13) adds: 'With the discontinuation and winding down of the clinical development of Decoy20, we expect our general and administrative expenses to decrease in the short term, however, this may be offset by additional costs related to any Post-Investment Transaction.'
- Removed:
- Older filing (2026-05-15) contains an overview paragraph describing the company's approach as based on the hypothesis that efficient activation of both innate and adaptive immune cells requires a multi-targeted package of immune system activating signals, and describing its patented technology, preclinical activity, Phase 1 Decoy20 trial in 2023, and May 2025 decision to conclude monotherapy enrollment; this paragraph is removed in the newer filing.
- Older filing (2026-05-15) contains a paragraph describing ongoing evaluation of strategic options for a Post-Investment Transaction including pursuing a strategic transaction involving investment in or acquisition of a target company, scientific validation, clinical and regulatory considerations, and resource availability; this paragraph is removed in the newer filing.
- Reworded:
- Older filing (2026-05-15) states the reverse stock split was effective June 26, 2025; newer filing (2026-08-13) states it was effective June 27, 2025.
- Older filing (2026-05-15) Overview states 'We are a clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.' Newer filing (2026-08-13) states 'We are a clinical-stage biotechnology company that has historically focused on developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy platform.'
- Older filing (2026-05-15) states 'We have discontinued further enrollment to the Combination Study and there are no participants remaining in the study.' Newer filing (2026-08-13) states 'Currently, we have discontinued further clinical development of Decoy20 and there are no participants remaining in the study.'
- Notes:
- The newer filing text appears to end abruptly mid-sentence at 'investor relations activities,' so changes after that point could not be assessed.
- The older filing text appears to end mid-sentence at 'the duration and completio', so changes after that point could not be assessed.
Risk Factors
- Added:
- Newer filing (2026-08-13) adds: In the executive management change risk factor, the sentence 'In addition, on April 16, 2026, Dr. Michael Newman, resigned as Chief Scientific Officer of the Company.'
- Newer filing (2026-08-13) adds an entire new risk factor: 'Our future business prospects and operations are uncertain, and we may be unable to identify or successfully execute a viable development program or strategic alternative.'
- Newer filing (2026-08-13) adds under Item 2(a): disclosure of a private placement completed on June 17, 2026, of 20,000,000 shares of Common Stock at $0.60 per share for gross proceeds of approximately $12.0 million, issued under Section 4(a)(2) and Regulation S.
- Newer filing (2026-08-13) adds under Item 2(b) and Item 2(c): the entries '(b) None.' and '(c) None.'
- Newer filing (2026-08-13) adds Exhibit 10.1: Form of Stock Purchase Agreement, dated June 17, 2026.
- Newer filing (2026-08-13) adds asterisk footnote '* Filed herewith' and pound footnote '# Furnished herewith' in the exhibit list (older filing had unmarked text without these symbols).
- Newer filing (2026-08-13) states the Rule 10b5-1 disclosure in Item 5 covers 'the six months ended June 30, 2026' instead of 'the three months ended March 31, 2026'.
- Removed:
- Older filing (2026-05-15) did not include Dr. Michael Newman's April 16, 2026 resignation in the executive management risk factor; the newer filing now includes it there.
- Older filing (2026-05-15) Item 2 under 'Unregistered Sales of Equity Securities and Use of Proceeds' contained only 'None.' instead of the subsection (a), (b), (c) structure present in the newer filing.
- Older filing (2026-05-15) did not include Exhibit 10.1 (Form of Stock Purchase Agreement, dated June 17, 2026) in its exhibit list.
- Reworded:
- Newer filing (2026-08-13) changes the period at the end of the heading 'Recent changes in executive management may create uncertainties during the Company's transition period' from a period to no change (the elder text had a period while newer has a line break with no period).
- Newer filing (2026-08-13) changes 'governance-related adjustments' to 'governance-related challenges' in the executive management risk factor.
- Newer filing (2026-08-13) changes 'Any such developments could create uncertainties that may adversely affect' to 'Any such developments could disrupt the Company's operations and strategic initiatives and adversely affect' in the executive management risk factor.
- In Item 5, newer filing (2026-08-13) changes the period for which no Rule 10b5-1 trading arrangements were adopted or terminated from 'the three months ended March 31, 2026' (older filing filed 2026-05-15) to 'the six months ended June 30, 2026'.
- Notes:
- The source texts provided are excerpts from the quarterly reports and combine the Risk Factors section with subsequent Items; the extracted Risk Factors text in the newer filing ends with the new 'future business prospects' risk factor before Item 2 begins.
- The provided texts appear to include content beyond just the Risk Factors section (e.g., Items 2-6, signatures); this comparison covers only the differences visible within these supplied excerpts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for INDP — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
1 institutional 13F filer reported holding INDP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 1
- Reported shares held 39,018
- Reported value $71,013
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about INDP's institutional holders → See what each manager we track holds →
Short interest (FINRA)
INDP had 822,250 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
INDP had 0.62% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.03 days to cover at the same settlement.
- Reported short interest (shares) 822,250
- Short interest (% of shares outstanding) 0.62%
- Prior settlement (shares) 916,352
- Reported change -10.27%
- Days to cover (reported) 1.03
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Frequently asked questions
What does Indaptus Therapeutics, Inc. (INDP) do?
Indaptus Therapeutics is a clinical-stage biotechnology company that historically developed a systemically-administered immunotherapy platform based on non-pathogenic, Gram-negative bacteria designed to activate innate and adaptive immune responses. The company has currently discontinued clinical development of its lead candidate, Decoy20, and is evaluating strategic alternatives, including potential business combinations, investments in other operating businesses, and new research initiatives…
What sector is Indaptus Therapeutics, Inc. (INDP) in?
Indaptus Therapeutics, Inc. (INDP) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is Indaptus Therapeutics, Inc. (INDP) overbought or oversold right now?
Indaptus Therapeutics, Inc. (INDP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 56, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INDP come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.